Phospho-JUN (S243) Antibody

What is the specific epitope recognized by Phospho-JUN (S243) antibodies?

Phospho-JUN (S243) antibodies specifically recognize c-Jun protein when phosphorylated at Serine 243. The immunogen typically consists of a synthetic phosphorylated peptide with the sequence P-L-S(p)-P-I derived from human c-Jun and conjugated to a carrier protein like KLH . This region corresponds to amino acids 210-259 of the human c-Jun protein, with the phosphorylated serine being the critical recognition element .

What applications are validated for Phospho-JUN (S243) antibodies?

Phospho-JUN (S243) antibodies have been validated for multiple experimental applications including:

These antibodies detect a protein band of approximately 43-48 kDa in Western blots, representing phosphorylated c-Jun .

What species reactivity is expected with Phospho-JUN (S243) antibodies?

Most commercially available Phospho-JUN (S243) antibodies demonstrate cross-reactivity with human, mouse, and rat samples . This multi-species reactivity is expected due to the high conservation of the c-Jun sequence surrounding the Ser243 phosphorylation site across mammalian species. Some antibodies also show reactivity with monkey (Mk) samples .

What is the recommended storage protocol for these antibodies?

Phospho-JUN (S243) antibodies should be stored at -20°C for up to one year from the date of receipt . It is essential to avoid repeated freeze-thaw cycles to maintain antibody functionality. Most preparations are supplied in PBS containing 50% glycerol, 0.02% sodium azide, and sometimes 0.5% BSA at pH 7.3-7.4, which helps maintain stability during storage .

How does phosphorylation at S243 regulate c-Jun function?

Phosphorylation at Ser243 plays a critical regulatory role in c-Jun function by:

• Reducing DNA-binding ability: Phosphorylation at S243 decreases c-Jun's ability to bind to its consensus DNA sequence (5'-TGA[GC]TCA-3')

• Promoting protein degradation: S243 phosphorylation serves as a priming event that facilitates subsequent phosphorylation events and promotes interaction with the SCF(FBXW7) ubiquitin ligase complex, leading to c-Jun ubiquitination and proteasomal degradation

• Downregulating c-Jun activity: The phosphorylation at S243 has been reported to participate in the downregulation of c-Jun function

This regulatory mechanism provides a fine-tuned control system for modulating the transcriptional activities of AP-1 complexes containing c-Jun.

What kinases are responsible for phosphorylating c-Jun at S243?

Several kinases have been identified that can phosphorylate c-Jun at Ser243:

• DYRK2 (Dual-specificity tyrosine-phosphorylation-regulated kinase 2): Functions as a priming kinase that phosphorylates S243, facilitating subsequent phosphorylation by GSK3B

• GSK3B (Glycogen synthase kinase 3 beta): Phosphorylates c-Jun at multiple sites including Thr-239, Ser-243, and Ser-249, with phosphorylation at these sites reducing c-Jun's DNA binding activity

These phosphorylation events create a sequential phosphorylation cascade that regulates c-Jun stability and function.

What are the critical controls when using Phospho-JUN (S243) antibodies?

When designing experiments with Phospho-JUN (S243) antibodies, researchers should include:

• Positive controls:

  • Lysates from cells treated with agents that activate pathways leading to S243 phosphorylation

  • Recombinant phosphorylated c-Jun protein standards

• Negative controls:

  • Samples treated with lambda phosphatase to remove phosphorylation

  • Samples from cells expressing phospho-deficient mutant (S243A)

  • Non-phosphorylated peptide competition assays

• Specificity controls:

  • Pre-absorption with phosphorylated immunizing peptide versus non-phosphorylated peptide

  • Comparison with total c-Jun antibody detection

Many commercial Phospho-JUN (S243) antibodies are affinity-purified using phosphopeptide chromatography, with non-phosphopeptide-reactive antibodies removed by chromatography on a non-phosphorylated peptide column , enhancing their specificity.

How can phosphatase inhibition improve detection of phosphorylated c-Jun?

Since c-Jun phosphorylation is dynamically regulated by both kinases and phosphatases, proper sample preparation is critical:

• Include comprehensive phosphatase inhibitor cocktails in all lysis buffers

• Pay particular attention to inhibiting calcineurin (PP2B), which specifically dephosphorylates c-Jun at Ser-243

• Maintain samples at 4°C throughout processing

• Use rapid sample processing methods to minimize time for phosphatase activity

• Consider including general phosphatase inhibitors such as sodium fluoride, sodium orthovanadate, and β-glycerophosphate

Research has shown that calcineurin-mediated dephosphorylation of c-Jun at Ser-243 results in increased stability of the c-Jun protein and enhanced tumorigenic ability , making phosphatase control crucial for accurate assessment of phosphorylation status.

How can the Phospho-JUN (S243) antibody be used to investigate cancer biology?

Phospho-JUN (S243) antibodies are valuable tools in cancer research:

• Clinical correlation studies: In clinical cervical cancer samples, enhanced c-Jun and decreased phospho-Ser-243 expression has been detected in 46% of cases, suggesting that dephosphorylation at this site may contribute to tumorigenesis

• Investigation of protein stability mechanisms: The half-life of c-Jun-S243A mutant (mimicking dephosphorylated state) is longer than that of wild-type c-Jun, indicating that dephosphorylation at this site enhances protein stability and potentially oncogenic function

• Tumor microenvironment studies: Monitoring c-Jun phosphorylation status in response to hypoxia, as PLK3-mediated phosphorylation following hypoxia or UV irradiation can increase DNA-binding activity

• Therapeutic response monitoring: Evaluating changes in c-Jun phosphorylation status following treatment with kinase inhibitors or other cancer therapeutics

What methods can be used to study the interplay between different c-Jun phosphorylation sites?

To understand the complex regulatory network of c-Jun phosphorylation:

• Multiple phospho-specific antibodies: Use antibodies targeting different phosphorylation sites (e.g., S243, S63, S73, T239) in parallel experiments

• Phospho-mutant expression: Express c-Jun with combinations of phospho-mimetic (S→D or S→E) and phospho-deficient (S→A) mutations at different sites

• Sequential phosphorylation analysis: Study the timing of different phosphorylation events using kinase inhibitors and time-course experiments

• Mass spectrometry approaches: Employ phospho-proteomics to identify all phosphorylation sites simultaneously and quantify their stoichiometry

• Proximity ligation assays: Investigate interactions between phosphorylated c-Jun and binding partners in situ

Research has shown that phosphorylation at S243 by DYRK2 primes c-Jun for subsequent phosphorylation by GSK3B at T239, creating a sequential phosphorylation cascade that regulates stability and function .

What strategies can improve signal-to-noise ratio when using Phospho-JUN (S243) antibodies in immunohistochemistry?

For optimal IHC results with Phospho-JUN (S243) antibodies:

• Antigen retrieval optimization: Test both heat-induced epitope retrieval (HIER) methods using citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) to determine optimal conditions

• Blocking optimization: Use bovine serum albumin (BSA) or normal serum from the species of the secondary antibody

• Dilution optimization: Test dilutions within the recommended range (1:50-1:200) to determine optimal concentration

• Signal amplification: Consider using polymer-based detection systems or tyramide signal amplification for low abundance phospho-epitopes

• Phosphatase controls: Include adjacent sections treated with lambda phosphatase to confirm phospho-specificity

• Counterstain selection: Choose counterstains that don't obscure nuclear localization of phospho-c-Jun signals

Why might Phospho-JUN (S243) signal be lost during sample preparation?

Several factors can contribute to loss of phospho-epitope detection:

• Dephosphorylation by active phosphatases: Specifically, calcineurin (PP2B) has been identified as a phosphatase that directly dephosphorylates c-Jun at Ser-243

• Inadequate fixation: Rapid fixation is essential to preserve phosphorylation status before phosphatases can act

• Proteolytic degradation: c-Jun is subject to ubiquitin-mediated degradation triggered by phosphorylation at S243

• Epitope masking: Protein-protein interactions or conformational changes may mask the phosphorylated epitope

• Sample handling: Extended processing at room temperature can result in dephosphorylation

Research has shown that silencing endogenous calcineurin expression leads to increased c-Jun ubiquitination and decreased stability , highlighting the dynamic nature of this phosphorylation site.

How does the DYRK2-GSK3B phosphorylation cascade regulate c-Jun?

The regulatory cascade involving DYRK2 and GSK3B represents a critical control mechanism:

• Initial priming: DYRK2 phosphorylates c-Jun at Ser-243, creating a priming site

• GSK3B recognition: This priming phosphorylation enables GSK3B to recognize c-Jun as a substrate

• Sequential phosphorylation: GSK3B then phosphorylates c-Jun at Thr-239, Ser-243, and Ser-249

• Functional consequence: This multi-site phosphorylation reduces c-Jun's ability to bind DNA, limiting its transcriptional activity

• Degradation promotion: The phosphorylated form interacts with SCF(FBXW7) ubiquitin ligase, leading to ubiquitination and proteasomal degradation

This regulatory mechanism provides precise control over c-Jun activity and protein levels in response to various cellular signals.

What is the relationship between c-Jun S243 phosphorylation and calcineurin in cancer?

Research has revealed an important regulatory axis between calcineurin and c-Jun S243 phosphorylation in cancer:

• Direct interaction: Calcineurin interacts with c-Jun in the nucleus of living cells, as demonstrated by fluorescence resonance energy transfer assays

• Dephosphorylation activity: Calcineurin specifically dephosphorylates c-Jun at Ser-243

• Stability regulation: This dephosphorylation increases c-Jun protein stability by preventing ubiquitination and subsequent degradation

• Transcriptional activity: Dephosphorylation enhances c-Jun-induced gene expression and increases c-Jun and Sp1 interaction

• Clinical correlation: In 46% of clinical cervical cancer samples, enhanced c-Jun and calcineurin expression with decreased phospho-Ser-243 levels were observed

These findings suggest that calcineurin-mediated dephosphorylation of c-Jun at Ser-243 enhances its tumorigenic ability by stabilizing the protein and increasing its transcriptional activity.

How might single-cell analysis techniques enhance our understanding of c-Jun S243 phosphorylation dynamics?

Emerging single-cell technologies offer new opportunities for studying c-Jun phosphorylation:

• Single-cell phospho-proteomics: Enables analysis of c-Jun phosphorylation heterogeneity within populations

• Live-cell imaging with phospho-sensors: Development of FRET-based biosensors for real-time monitoring of c-Jun phosphorylation status

• Spatial transcriptomics correlation: Linking c-Jun phosphorylation states to localized transcriptional outputs within tissue architecture

• Single-cell ChIP-seq: Correlating phosphorylation status with genomic binding patterns at the single-cell level

• Microfluidic approaches: Studying rapid kinetics of phosphorylation/dephosphorylation events following stimulation

These approaches could reveal how heterogeneity in c-Jun phosphorylation contributes to cellular decision-making in normal development and disease states.

What is the therapeutic potential of targeting pathways that regulate c-Jun S243 phosphorylation?

Considering the role of c-Jun in cancer and other diseases, targeting its regulatory phosphorylation represents a promising therapeutic approach:

• DYRK2 inhibitors: Could prevent the priming phosphorylation at S243, potentially stabilizing c-Jun in contexts where its activity is beneficial

• Calcineurin modulators: Might regulate c-Jun stability by affecting its dephosphorylation at S243, particularly relevant in cancers showing enhanced calcineurin and c-Jun expression

• GSK3B pathway targeting: Could influence the phosphorylation cascade that regulates c-Jun DNA binding

• Phosphatase-kinase balance modulation: Developing drugs that shift the equilibrium between phosphorylation and dephosphorylation at this site

• Degradation pathway intervention: Compounds affecting the interaction between phosphorylated c-Jun and the ubiquitination machinery